Parkman Healthcare Partners LLC Has $4.65 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Parkman Healthcare Partners LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 47.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 37,751 shares of the specialty pharmaceutical company's stock after selling 34,505 shares during the period. Parkman Healthcare Partners LLC owned 0.06% of Jazz Pharmaceuticals worth $4,649,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the last quarter. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Allianz SE bought a new position in Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the period. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:JAZZ opened at $102.91 on Wednesday. The company has a market capitalization of $6.34 billion, a P/E ratio of 14.49, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a 50-day simple moving average of $118.23 and a 200 day simple moving average of $122.25.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the business earned $2.68 EPS. The business's quarterly revenue was down .5% on a year-over-year basis. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Royal Bank of Canada dropped their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Morgan Stanley reduced their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $182.79.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 4,813 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. The trade was a 10.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,236 shares of company stock valued at $3,956,190. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.